2014 New Patent covering therapeutic application of HPH-116 is granted
Virus-based vaccine composition having a protein with zinc finger pattern(s), method of preparing and using same
2015: On March 16, 2015 patent EU 09151596.5 (notification following Rules 71.3 CE) was granted and validated. In 2015, azodicarbonamide (HPH-116) stay the sole safe drug administrable to man.
Vaccine composition made of at least one virus strain exhibiting at least one protein having zinc finger motifs, comprises: virus in an inactivated state in which zinc was ejected from the protein by one redox reaction with azodicarbonamide, where the virus is entire and has a viral envelope intact after inactivation; biurea formed from azodicarbonamide during the redox reaction; and optionally an unreacted azodicarbonamide residue. An independent claim is included for preparing the vaccine composition, comprising: contacting the virus strain exhibiting the protein with micronized azodicarbonamide; penetrating micronized azodicarbonamide through the viral envelope of virus by leaving the envelope intact; and inactivating the virus by a redox reaction between micronized azodicarbonamide and the protein resulting by an ejection of the zinc from the protein and a partial decomposition of azodicarbonamide into biurea. - ACTIVITY : Virucide. - MECHANISM OF ACTION : Vaccine.
Annual Safety Report/Azodicarbonamide
POC Clinical trial report
In this annual safety report, all safety information on HPH116 (ADA) received and assessed by the sponsor in the period from 08-Mar-2007 up to and including DLP 10-Mar-2008 has been reviewed. In conclusion, no specific areas of concern have been identified during the reporting period. No single SAR was reported in the exposed clinical trial with 33 HIV patients; this confirms the beneficial safety profile of HPH116. During the period of this annual safety report no significant safety-related issues have been identified. All relevant information stated in this report will be incorporated in the next update of the IB.
2015 H-Phar" on the ground"
1° Collaboration with NGO MUTTI recognized in Belgium and in Democratic Republic of Congo: in the bush
(Belgium), Friday June, 10; 2005
H-Phar announces that its galena form HPH116 successfully
achieves a phase 1 clinical trial including 50 healthily volunteers
in “D.R.U.G.” located in University Hospital Gent,
De Pintelaan 185, B-9000 Gent, Belgium. No adverse events were
reported at doses up to 6.000 mg of active compound (1 day)
and 2.400 mg (7days). In particular, the kidney function was
carefully followed using erythrocytes and lymphocytes counts
Surrogate markers of tubular, interstitial and glomerular cells
injuries were measured. No casts or crystals in urine were
observed using flow cytometry (1). Urinary casts are formed
only in the distal convoluted tubule (DCT) or the collecting
duct (distal nephron). The proximal convoluted tubule (PCT)
and loop of Henle are not locations for cast formation. Red
blood cells may stick together and form red blood cell casts.
Such casts are indicative of glomerulonephritis, with leakage
of RBC's from glomeruli, or severe tubular damage. White blood
cell casts are most typical for acute pyelonephritis, but they
may also be present with glomerulonephritis. Their presence
indicates inflammation of the kidney, because such casts will
not form except in the kidney. Kidney follow up was completed
by urine markers: retinol binding protein (index of proximal
tubular injury) - b2-microglobulin (Low molecular weight molecule
B2 microglobulin, has a molecular weight of about 25000. This
small protein is easily filtered across the basement membrane
and then normally completely reabsorbed by the proximal tubular
cells. A variety of diseases that produce tubular and interstitial
injury impair the tubular reabsorption of this molecule). -
b-NAG (N-acetyl-beta-glucosaminidase) (Among patients with
predominantly glomerular disorders there was a close relationship
between activity of the disease and Nacetyl- beta-glucosaminidase
concentration). None of those parameters showed significant
variations during the Phase 1 clinical trials.
In combination with the ICH animal models required
pre clinical data (including renal histological examinations),
this finding seems to exclude kidney toxicity of HPH116.
(1) Clinical Chemistry. 1999;45:118-122.
© 1999 American Association for Clinical Chemistry, Inc.
Automated Flow Cytometry Compared with an Automated Dipstick Reader for Urinalysis
Michel R. Langlois1, Joris R. Delanghe1, Sophia R. Steyaert1, Karel C. Everaert2
and Marc L. De Buyzere1
Departments of 1 Clinical Chemistry and 2 Urology, University Hospital Gent,
De Pintelaan 185, B-9000 Gent, Belgium.
Personne de contact:
Docteur Michel Vandevelde
14, avenue des Bouvreuils B-1301 Bierges Belgium
TÚl. +32 10 41 70 78 Fax 32 10 41 42 47